Dendritic cell immunotherapy: Stumble and expects

Cellular immunotherapy such as that initiated by dendritic cell (DC) is capable of eradicating cancer stem cells and restoring the homeostasis imbalance, and therefore has emerged as a promising approach to cure tumor. The first therapeutic DC vaccine in world has been approved by American FDA. However, the satisfactory therapeutic benefits of DC vaccine observed in vitro and in vivo (animal) studies could barely be recapitulated in clinical settings. The advantages of DC immunotherapy, achievements and challenges are introduced.